 NEWARK, Calif., June 14, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq:PTGX, a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 100,000,000 of shares of its common stock. 